Evidence map›Paper›PMID 42082885›Full record

SynthesisClinical pharmacokinetics2026

Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools.

Nada Dia, Yannick Hoffert, Angela Elma Edwina, Jos Tournoy, Isabel Spriet, Erwin Dreesen

Abstract readSystematic ReviewComparative Study
PubMed Publisher
In one paragraph

Synthesis in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nada DiaDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, Box 521, 3000, Leuven, Belgium.ORCID 0000-0003-1818-1949
Yannick HoffertDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, Box 521, 3000, Leuven, Belgium.ORCID 0000-0002-1631-9484
Angela Elma EdwinaDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.ORCID 0000-0001-6180-473X
Jos TournoyDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.ORCID 0000-0002-0265-9154
Isabel SprietDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, Box 521, 3000, Leuven, Belgium.ORCID 0000-0001-6342-0676
Erwin DreesenDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, ON2 Herestraat 49, Box 521, 3000, Leuven, Belgium. erwin.dreesen@kuleuven.be.ORCID 0000-0002-0785-2930

Funding

Fonds Wetenschappelijk Onderzoek 1SHAA24NH2020 Marie Skłodowska-Curie Actions 956146Onderzoeksraad, KU Leuven KGG-E1099-STG/21/005
6 · The paper itself

Abstract

BACKGROUND AND

objectivesVancomycin is a widely used antibiotic with a narrow therapeutic window and considerable pharmacokinetic variability, necessitating accurate and precise dosing. Population pharmacokinetics (popPK) models have become essential for facilitating model-informed precision dosing (MIPD) of vancomycin. We aimed to summarise and compare popPK models of vancomycin and evaluate MIPD software modules incorporating these models.

methodsWe systematically searched PubMed, EMBASE, and reference lists of relevant articles from inception through 01 January 2026 to identify articles describing the development of compartmental, one-stage parametric popPK models based on data from adult patients (aged ≥ 18 years) receiving intravenous vancomycin. We extracted and summarised key information on study design, patients, vancomycin dosing regimens, sampling strategies, quantification methods, modelling techniques, and covariates. We contacted providers of MIPD software tools and invited them to complete an online questionnaire assessing the features and clinical integration of their vancomycin module. We evaluated the incorporated models and their clinical applicability.

resultsWe identified 99 adult-applicable vancomycin popPK models across 97 articles: 48 (48.5%) were one-compartment, 47 (47.5%) two-compartment models, and 4 (4.0%) three-compartment models. Kidney function estimators and body weight metrics were the most commonly retained covariates on clearance and volume of distribution, respectively. Of 18 identified MIPD software tool providers, 13 (72.2%) completed the questionnaire, confirming the inclusion of vancomycin modules. These tools incorporated a total of 101 vancomycin models, of which 48 were intended for adults. Three tools had been evaluated in prospective non-interventional studies, and two in a prospective interventional trial. Five tools were certified as conforming to European Union (EU) regulatory standards under the Medical Devices Directive and were in the process of obtaining EU conformity under the Medical Device Regulation. Mapping published models to tool implementations revealed partial overlap, limited transparency on model selection and lack of model‑level external validation, underscoring the need for structured evaluation before routine clinical adoption.

conclusionThis review presents a comprehensive overview of vancomycin popPK models and MIPD software modules for adult patients. Our findings highlight the diversity among popPK models and the need for standardised reporting, transparent model selection, and prospective evaluation to support clinical implementation of MIPD.

Indexed as

Anti-Bacterial AgentsModels, BiologicalSoftwareVancomycinAdultHumansPrecision MedicineAnti-Bacterial AgentsVancomycin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.